BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nexletol (Bempedoic acid) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nexletol (Bempedoic acid)\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07623915-6854@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nexletol (Bempedoic acid): Phase 3 readout est. (NCT07623915)
DESCRIPTION:Nexletol (Bempedoic acid)\, phase 3\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: A Clinical Study to Evaluate the Efficacy and Safet
 y of Bempedoic Acid\nEstimated primary completion: 30 June 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/bempedoic-acid#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07623915
URL:https://assetmemo.bio/drug/bempedoic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07440381-6854@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nexletol (Bempedoic acid): Phase 3 readout est. (NCT07440381)
DESCRIPTION:Nexletol (Bempedoic acid)\, phase 3\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: triPle Oral thERapy With Bempedoic Acid vs uSual Ca
 re in Early Lipid Management of Patients With acUte coronAry synDromE\nEst
 imated primary completion: August 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/bempedoic-acid#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07440381
URL:https://assetmemo.bio/drug/bempedoic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07824323-6854@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Nexletol (Bempedoic acid): Phase 4 readout est. (NCT07824323)
DESCRIPTION:Nexletol (Bempedoic acid)\, phase 4\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: Early Triple Lipid-Lowering Therapy With Bempedoic 
 Acid After Acute Coronary Syndrome\nEstimated primary completion: March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/bempedoic-acid#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078243
 23
URL:https://assetmemo.bio/drug/bempedoic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05488431-6854@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Nexletol (Bempedoic acid): Phase 2 readout est. (NCT05488431)
DESCRIPTION:Nexletol (Bempedoic acid)\, phase 2\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: Cholesterol and Inflammation Lowering Via Bempedoic
  Acid\, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)\nEstimate
 d primary completion: 1 March 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/bempedoic-acid#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05488431
URL:https://assetmemo.bio/drug/bempedoic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07282821-6854@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Nexletol (Bempedoic acid): Phase 2 readout est. (NCT07282821)
DESCRIPTION:Nexletol (Bempedoic acid)\, phase 2.\nStudy: Bempedoic Acid The
 rapy for Polycystic Kidney Disease\nEstimated primary completion: 30 Septe
 mber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bempedoic-
 acid#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07282821
URL:https://assetmemo.bio/drug/bempedoic-acid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
